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Rheumatoid arthritis: Biological therapy other than anti-TNF 
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Abstract 
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and is characterized by 
synovitis that causes joint damage. The introduction of biologic agents has made it possible to induce 
remission in many patients and inhibit joint damage. Activated T cells in RA patients proliferate and 
stimulate the production of pro-inflammatory cytokines including tumor necrosis factor (TNF) and 
interleukin 6 that play important roles in RA pathogenesis. The most widely used biologic agents indicated 
for RA inhibit the activity of TNF. However, newly developed biologic drugs targeting different pathways are 
now currently part of the therapeutic options to induce remission in patients with RA. The present review 
focuses on biologic agents directed at molecular targets different from TNF and addresses the possible 
advantages of these drugs. 
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1. Introduction 
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and is characterized by 
synovitis that causes joint damage. The introduction of biologic agents has made it possible to induce 
remission in many patients and inhibit joint damage. Therefore, it is important to assess the long-term 
outcomes of treatment with biologic therapies, to ensure that they are safe and tolerable and continue to 
offer clinical benefit. Activated T cells in RA patients proliferate and stimulate the production of pro-
inflammatory cytokines [1], [2], [3] and [4] including tumor necrosis factor (TNF) and interleukin 6 that play 
important roles in RA pathogenesis. The most widely used biologic agents indicated for RA inhibit the 
activity of tumor necrosis factor (TNF). However, newly developed biologic drugs target interleukins (ILs), 
especially IL 6. Moreover, RA treatments targeting B and T cells have also been a focus of research, based 
on the profile of serological markers, including rheumatoid factor (RF) and anti-citrullinated cyclic peptide 
(anti-CCP), and the results of studies show infiltration of numerous CD4-positive T cells and expression of 
major histocompatibility complex (MHC) class II molecules in the synovial membrane [5]. Recent studies 
also revealed the importance of T-helper cells (Th)17 [6]. The present review focuses on biologic agents 
directed at molecular targets different from TNF and addresses the possible advantages of these drugs. 
 
2. Abatacept 
Abatacept (ABA) is a soluble recombinant human CTLA 4-Ig fusion protein comprising the extracellular 
domain of human CTLA-4 and a fragment of the Fc domain of human IgG1 that selectively modulates the 
CD80/CD86:CD28 co-stimulatory signal required for full T-cell activation [7]. The unique upstream 
mechanism of ABA impacts downstream inflammatory mediators and autoantibodies. For instance, reverse 
signaling to antigen-presenting cells (APCs) upon binding of CTLA 4-Ig to CD80/CD86 might also interfere 
with APC activation and function [8] and [9]. Whether such signaling or other CTLA 4-Ig-mediated effects 
contribute to a beneficial or adverse outcome, is not entirely clear so far. ABA has demonstrated significant 
improvements in both clinical efficacy and physical function, and has been shown to significantly reduce 
the progression of structural damage in 1-year, blinded, randomized, placebo-controlled trials of patients 
with established RA and an inadequate response to methotrexate (MTX) [10], [11] and [12]. ABA was 
initially available as an intravenous (IV) formulation. More recently, a subcutaneous (SC) formulation has 
also become available. 
Multiple measures of efficacy were examined to evaluate the impact of treatment on multiple aspects of 
the disease, in addition to assessing clinical, functional, and HRQoL outcomes individually. At year 7, > 40% 
of all patients achieved remission together with normalized mHAQ. These data, which evaluated the 
response to treatment from different endpoints, suggest that the clinical efficacy benefits seen with ABA 
plus MTX are accompanied by improvements in function and HRQoL that are meaningful to patients [13]. In 
combination with MTX, ABA proved to be able to deliver significant clinical benefits that were maintained 
over the long term, in patients with established RA and an inadequate response to MTX. ABA is currently 
prescribed to patients with RA uncontrolled by normal doses of existing disease-modifying antirheumatic 
drugs (DMARDs). The dosing regimen is based on patient weight (500 mg for < 60 kg, 750 mg for 60–100 kg, 
and 1000 mg for > 100 kg). The SC ABA is administered at a dose of 125 mg/week. Due to a greater impact 
on naïve T cells, there is a rationale for the use of ABA in early RA. Importantly, some patients also 
experienced long lasting normalization of physical function and HRQoL. These findings support the use of 
ABA in patients with RA and an inadequate response to MTX, to obtain early, effective, and sustained 
clinical and functional outcomes. Of interest, cohort studies suggest a role for ABA administered as a 
monotherapy, and we achieved results comparable to the combination therapy in five patients who had 
experienced a definite increase of liver enzymes by both MTX and Azatioprine (manuscript submitted). ABA 
has a favorable safety profile, particularly in relation to serious (including opportunistic) infections in 
comparison with anti-TNF agents [14], [15], [16], [17] and [18]. The most common infections reported are 
pneumonia, urinary tract infection and cellulitis. As regards the risk of malignancies, the reported 
malignancy rates were not higher in patients treated with ABA than in those not treated with biological 
agents. Antibodies to ABA developed in ≤ 3% of patients, with no association between immunogenicity and 
adverse events [19]. 
3. Tocilizumab 
Tocilizumab (TCZ), a recombinant humanized anti-human IL-6 receptor monoclonal antibody, provides 
another alternative to anti-TNF-α therapy [20]. TCZ was introduced in 2010 for the treatment of RA [21] 
and has been approved for use in patients with active moderate to severe disease who have previously 
failed DMARDs [22]. IL-6 is a pleiotropic cytokine with various biologic activities, including induction of the 
acute-phase reaction, regulation of the immune response and promotion of hematopoiesis [23] and [24]. In 
RA patients, elevated levels of IL-6 seen in the serum and synovial fluid of affected joints [25], [26] and [27] 
are associated with disease activity, clinical manifestations of RA and joint destruction [28], [29] and [30]. 
The inhibition of IL-6 signals by TCZ reduces systemic inflammation, RA synovitis, and bone and cartilage 
damage, and may have beneficial cardiovascular effects. The antibody was humanized by grafting a 
complementarity-determining region from a mouse anti-human IL-6R mAb. TCZ has been shown to bind to 
the membrane-bound and soluble forms of human IL-6R, and to inhibit IL-6 function [31]. TCZ can be 
administered in monotherapy without loss of efficacy when patients do not tolerate methotrexate or 
synthetic DMARDs. TCZ, either as monotherapy or in combination with MTX, was significantly more 
efficacious than MTX alone [32] and it is possibly superior to adalimumab in monotherapy. The FDA-
recommended dose is 4 mg/kg administered via the IV route every 4 weeks, and 162 mg administered via 
the subcutaneous route every other week, followed by an increase to 8 mg/kg (i.v., q4w) or 162 mg (s.c., 
qw) based on clinical response [33] and [34]. SC formulations of biologic DMARD have been developed in 
order to facilitate their use outside hospitals by permitting self-administration. 
 
TCZ might be particularly effective for RA patients with a high systemic inflammatory response, anemia, AA 
amyloidosis and other diseases mediated by IL-6 and the European League Against Rheumatism (EULAR) 
2013 update recommends TCZ use as a first biologic agent for monotherapy (without MTX) [35]. TCZ is 
highly effective with an ACR/EULAR remission rate of 35.1% and drug continuation rate at 3 years of 68.2% 
in routine clinical practice. Among the patients with remission, the majority remained in remission or had 
low disease activity. In general, TCZ was well tolerated in clinical trials for monotherapy and in combination 
with MTX or as DMARD [36] administered via IV or SC routes [37]. The safety profile is similar to anti-TNF in 
both the short term and the long term. Nevertheless, a number of side effects have been reported in 
patients treated with TCZ. The most common adverse events were infection, gastrointestinal complaints, 
rash, headache and biochemical abnormalities (including increased levels of lipids and liver enzymes) and 
infusion/hypersensitivity reactions [38]. In patients with considerable comorbidity TCZ therapy has been 
associated with an increased risk of gastrointestinal perforation, opportunistic infections and tuberculosis 
[33]. Apart from RA, TCZ has also been used in Castleman disease and in non-RA systemic inflammatory 
rheumatic diseases [39]. A possible new indication of TCZ might be a particular condition of inflammatory 
symmetrical erosive polyarthritis combined with clinical features of SLE [40], [41] and [42] known as 
“Rhupus”. IL-6 levels are elevated in active Rhupus [42], and we successfully treated 3 patients of refractory 
Rupus who were at high risk for long lasting high dose of corticosteroids. TCZ, given monthly at the dose of 
8 mg/kg, allowed early reduction of corticosteroid dose even in 2 out of 3 patients who were 
corticosteroid-dependent, and resistant/intolerant to other biological drugs, including TNF-inhibitors, anti-
CD20, and ABA. 
4. Rituximab 
Rituximab (RTX), a monoclonal chimeric anti-CD20 antibody, recognizes a determinant expressed on 
intramedullary pre-B- to B-memory-stage lymphocytes. The first controlled trial on RA was published in 
2004 [43]. Because B cells, the target of RTX, play pivotal roles in RA pathogenesis [44], serum biomarkers 
of B cell activation, such as the presence of RF, or anti-CCP antibodies and elevated IgG level, were 
identified as potential predictors of response to RTX. Depleting the majority of circulating B-cells induces 
clinical remission which can last for many months before relapse [45]. Peripheral blood B cell re-population 
after RTX treatment is similar to what is observed after bone marrow transplantation, and predominantly 
involves a subset of naïve or antigenically inexperienced transitional B cells derived from an immature 
population. RTX is approved in the European Union and the USA for the treatment of RA after inadequate 
response to at least one TNF-inhibitor. It is currently prescribed as a second line treatment of active RA in 
association with methotrexate. However, in daily practice, RTX can be administered without methotrexate 
in patients with intolerance or previous adverse event to this drug [46]. The combination of RTX 
administered IV as two 1000 mg infusion cycles separated by 15 days and methotrexate is highly effective 
at reducing disease activity at 6 months in RA. However, 35% of patients do not achieve a significant 
response and, among those who initially respond, relapse in the next 6–12 months often occurs [43]. A new 
cycle is initiated after disease activity recurs. The GISEA registry-based study showed a good efficacy for 
RTX with a mean reduction of DAS 28 at 52 weeks of more than 1.50 points, with maintenance over two 
years. No significant differences were observed for patients treated or not with MTX both for mean DAS 28 
and HAQ variation and achievement of disease remission [47]. 
Patients seronegative for rheumatoid factor and anti-cyclic citrullinated protein have worse responses, 
suggesting that these patients have non-B-cell-mediated disease and require a different therapeutic 
approach [48] and [49]. Despite the fact that RTX does not deplete fully matured plasma cells, repeated 
administration of the biologic agent frequently induces a reduction of immunoglobulins, particularly 
immunoglobulin G (IgG), which may carry an increased risk of infection. 
 Before commencement of RTX, hepatitis B serology and liver function tests should be routinely performed. 
Reactivation of occult hepatitis B infection has been reported in patients with RA treated with RTX. On the 
other hand specific safety profile of RTX indicates an apparent absence of increased risk of reactivation of 
tuberculosis, a low risk of opportunistic infections, but possibly a small increased risk of the very rare but 
serious neurological infection progressive multifocal leukoencephalopathy, the risk of which may be higher 
in patients with previous immunosuppression. 
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